Alzheimer’s Disease

Lecanemab: drawbacks to consider

Lecanemab: a review

FDA approval of lecanemab: what does the data tell us about the amyloid hypothesis?

Lecanemab vs aducanumab

Primary care digital screening tool for Alzheimer’s disease

Clinical robustness of CSF pTau/Aβ42 ratio for Alzheimer’s disease diagnosis

Remaining challenges in bringing fluid biomarkers into clinical practice

Bringing the pTau/Aβ42 biomarker into the clinic

Promise of microRNAs as Alzheimer’s disease markers

Targeting the pancreas to treat Alzheimer’s disease

Diabetes-associated cognitive dysfunction

Mild behavioral impairment is associated with abnormal AD CSF biomarker profiles in MCI

New pivotal study using photobiomodulation in Alzheimer’s treatment

The regulatory role of nicotinic receptors in cognitive functioning

The importance of using systems biology based approaches in AD research

How effective are cholinergic agents beyond MCI?